Cambridge Cancer Genomics
The health technology company is building tools to enable oncologists to make the best therapeutic decisions for their patients.
Cambridge Cancer Genomics is backed by Y Combinator, the California seed accelerator, incorporated in the UK and anchored in Cambridge. It also has a key alliance with the globally respected Comprehensive Blood & Cancer Centre in Bakersfield, California among other partnerships on both sides of the Pond.
The company is soon to embark on a fresh round of fundraising to fuel its R & D activities. CCG is reluctant to forecast exact figures but, assessing the traction already secured by the startup and its transatlantic potential, it could raise anything between $20m and $50m.
It has already raised around $4.5m seed capital, Business Weekly understands.